20.1 C
New York

Tag: guide

Bitcoin Options Expire

The bitcoin and ethereum options on Deribit, one of the largest crypto derivatives exchange, expired earlier today. This month saw the largest open interest in...

Top News

Weimob (2013.HK) Smart Retail sends SaaS revenues soaring 90.9%

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

SHANGHAI, Mar 31, 2022 - (ACN Newswire) - Weimob Inc (2013.HK) released its 2021 financial report earlier this week (3-28), showing that its adjusted total revenue in 2021 reached 2.686 billion yuan, a record high, and its performance increased by 36.4% against the background of overcoming unfavorable factors such as downward pressure on the macro economy. After adjustment, the gross profit of RMB 1.517 billion increased by 51.3% year on year. Among them, the digital business sector achieved revenue of 1.967 billion yuan, an increase of 70.9% compared with 2020. Subscription solutions and merchant solutions in this sector achieved high growth of 90.9% and 47.5% respectively. The "WOS" new business operating system developed by Weimob Inc has been officially put into beta this month, and it may become a powerful engine to drive the future growth of Weimob Inc.

High-speed growth of business; SaaS revenue grows against the trend

In 2021, the persistence of the epidemic brought many challenges to consumers and To B enterprises. Weimob Inc focuses on the digital transformation and upgrading of enterprises, continuously strengthens the development of multi-product lines, further promotes the three strategies of "customization, ecology and internationalization", overcomes the adverse effects of external environment, and achieves the contrarian growth of performance. The financial report shows that the digital business income of Weimob Inc in 2021 was 1.967 billion yuan, an increase of 70.9% compared with 1.246 billion yuan in 2020. Among them, the revenue of Weimob Inc subscription solution (SaaS sector) reached 1.188 billion yuan, a substantial increase of 90.9% year-on-year. The number of paying merchants was 102,813, a year-on-year increase of 5.0%. The average income per user increased by 57.7% to 11,553 yuan.

At the same time, with the continuous promotion of TSO's full-chain marketing solution, the business solutions in the digital business sector of Weimob Inc have achieved good results. The financial report shows that in 2021, the business solution revenue was 779 million yuan, a year-on-year increase of 47.5%; The gross income of accurate delivery was 10.95 billion yuan, a year-on-year increase of 12.1%. The number of paying merchants increased by 26.7% to 57,909, and the average income per user was 13,454 yuan.

The financial report shows that the R&D expenditure of Weimob Inc in 2021 was 775 million yuan. Among them, the total investment of strategic projects such as the new business operating system WOS and the construction and operation of the middle platform reached 682 million yuan. Due to the increased investment in R&D and the merger and acquisition of Xiangxinyun and Haiding in 2021 and previous years, Weimob Inc lost 566 million yuan in adjusted net profit in 2021. However, these investments promote the cost reduction and efficiency increase of Weimob Inc. The financial report shows that the company has abundant cash flow, with cash and cash equivalents of 3.809 billion yuan, and its financial structure is healthy and sustainable.

The strategy of customization has achieved fruitful results, and internationalization has steadily advanced
The financial report shows that the reason why Weimob Inc achieved high revenue growth in 2021, benefiting from the core strategy of "customization, ecology and internationalization" of the group. With the support of TSO's full-chain marketing solution and smart retail and other key businesses, Weimob Inc's customization strategy achieved fruitful results. In the smart retail sector, in 2021, Weimob Inc's smart retail revenue was 426 million yuan, 193.6% year-on-year, and its share in subscription solution revenue further increased from 20.2% in 2020 to 36%. At present, the number of smart retailers in Weimob was 6,126, the number of brand merchants was 1,003, and the average order income of brand merchants per user was 234,000 yuan.

The Weimob smart catering business also achieved a breakthrough. In 2021, Weimob Smart Catering completed the technical and operation system layout of "three stores integrated and global operation". During the reporting period, Weimob's smart catering revenue was 53.616 million yuan, up 19.6% year-on-year, accounting for 4.5% of subscription solution revenue. There were 8,406 smart catering merchants, and the average order revenue per user of catering merchants was 17,000 yuan. By the end of 2021, Weimob smart catering customers accounted for 41% of China's top 100 restaurants; The revenue from catering orders accounted for 51%.

Promoting ecology, WOS New Business Operating System as a new growth engine

As one of its three core strategies, Weimob Inc's ecological strategy has also made remarkable achievements. In terms of developer ecology, in 2021, Weimob Cloud PaaS platform will continue to empower ecological partners, with over 50 new high-quality ecological partners and over 400 new cloud market applications.

In order to create a good foundation for smart business, the WOS New Business Operating System was officially put into public beta in March 2022. WOS new commercial operating system integrates SaaS business integration, ecological partnership and PaaS platform infrastructure, and realizes the comprehensive upgrade of product strength, technical strength and ecological strength, demonstrating the technical strength of Weimob Inc.

In 2022, Weimob will continue to improve WOS product strength, better serve customers through Weimob cloud empowering eco-partners, and drive the growth of product strength and commercial strength by technology, so as to realize faster product development, better product experience and service, and more ecological applications and services, so as to promote customers' purchase, increase customer renewal fees and increase ecological income. CITIC Securities holds that "WOS" is expected to become the new growth driver of SaaS with the improvement of merchant coverage and the acceleration of commercialization.

In terms of investment layout, in 2021, Weimob Inc and Yicun Capital jointly established "Weizhi Digital Industry Fund" and invested in outstanding projects such as Shuyun, Haizhi and Meichuang. In November, 2021, Weimob Inc announced the acquisition of 51.89% equity of Shanghai Xiangxinyun Network Technology Co., Ltd., and incorporated Xiangxinyun into the listed company system, thus deepening the digitalization capability of smart retail shopping guide.

Weimob Inc said that in 2022, the company will focus on seven directions: focusing on key customers and continuing to lead; Open and win-win, create ecological barriers; TOS full-link operation, helping customers smart grow; Continue to increase investment in private track and consolidate the leading position in the industry; Cloudy layout drives new growth; "7+X" to create a new growth flywheel; Cross-border development and layout of the global market. Under the background of accelerating the digitalization process of Chinese enterprises, Weimob Inc has made sufficient product reserves, technical reserves, talent reserves and capital reserves, laying a solid foundation for the development in the next five years.

Media contact:
Micky Sun, Weimob Inc
Email: jingyi.sun@weimob.com
Website: http://www.weimob.com

Weimob Inc (2013.HK) is the leading cloud-based commerce and marketing solutions provider for SMBs. For information, visit www.weimob.com.

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comWeimob Inc (2013.HK) released its 2021 financial report this week (3/28), showing that its adjusted total revenue in 2021 reached 2.686 billion yuan, a record high, and its performance increased by 36.4% against the background of overcoming unfavorable factors such as downward pressure on the macro economy.

AuroraFS To Launch Web3Tube Phase 3 Airdrop

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass AdoptionThe AuroraFS is ready to release the first fully decentralized media streaming platform. Web3Tube is the decentralized streaming platform to ...

Read More...

AuroraFS To Launch Web3Tube Phase 3 Airdrop

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass AdoptionThe AuroraFS is ready to release the first fully decentralized media streaming platform. Web3Tube is the decentralized streaming platform to ...

Read More...

How To Heat Your Home With Bitcoin Mining

This guide walks you through integrating a bitcoin mining rig into your home’s HVAC system, recapturing heat from the process and saving money.

How to Add BSC to MetaMask A Step-by-Step Guide to Using Binance Smart Chain With MetaMask

This primer will show you one of the most popular moves in DeFi.

Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Tokyo and Salt Lake City, Indianapolis, Mar 25, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of vision and kidney disease.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Image of the AI grouping patients and analyzing the treatment patterns & efficacy

For this smaller group of patients, physicians may have limited clinical decision-making experience or evidence-based guidance for choosing drug combinations. The solution is to expand the number of patients to support development of general principles to guide decision- making. Combining patient data from multiple healthcare institutions, however, requires deep expertise in artificial intelligence (AI) and wide-ranging experience in developing machine learning models using sensitive and complex healthcare data.

Hitachi, U of U Health, and Regenstrief researchers partnered to develop and test a new AI method that analyzed electronic health record data across Utah and Indiana and learned generalizable treatment patterns of type 2 diabetes patients with similar characteristics. Those patterns can now be used to help determine an optimal drug regimen for a specific patient.

Some of the results of this study are published in the peer-reviewed medical journal, Journal of Biomedical Informatics, in the article, "Predicting pharmacotherapeutic outcomes for type 2 diabetes: An evaluation of three approaches to leveraging electronic health record data from multiple sources". (bit.ly/3NvD7BE)

Hitachi had been working with U of U Health for several years on development of a pharmacotherapy selection system for diabetes treatment(1) . However, the system was not always able to accurately predict more complex and less prevalent treatment patterns because it did not have enough data. In addition, it was not easy to use data from multiple facilities, as it was necessary to account for differences in patient disease states and therapeutic drugs prescribed among facilities and regions. To address these challenges, the project partnered with Regenstrief to enrich the data it was working with.

The new AI method initially groups patients with similar disease states and then analyzes their treatment patterns and clinical outcomes. It then matches the patient of interest to the disease state groups and predicts the range of potential outcomes for the patient depending on various treatment options. The researchers evaluated how well the method worked in predicting successful outcomes given drug regimens administered to patients with diabetes in Utah and Indiana. The algorithm was able to support medication selection for more than 83 percent of patients, even when two or more medications were used together.

In the future, the research team expects to help patients with diabetes who require complex treatment in checking the efficacy of various drug combinations and then, with their doctors, deciding on a treatment plan that is right for them. This will lead not only to better management of diabetes but increased patient engagement, compliance, and quality of life.

The three parties will continue to evaluate and improve the effectiveness of the new AI method and contribute to future patient care through further research in healthcare informatics.

Hitachi will accelerate efforts, including the practical application of this technology through collaboration between its healthcare and IT business divisions and R&D group. GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, is promoting healthcare- related projects in the U.S., will also deepen the collaboration in this field. Through these efforts, the entire Hitachi group will contribute to the health and safety of people.

(1) Hitachi, Ltd. news release, March 12, 2018 "Pharmacotherapy Selection System Supports Shared Clinician- patient Decision-Making in Diabetes Treatment"
bit.ly/3Ld97Z7
Hitachi, Ltd. news release, February 27, 2019 "New Clinical Study Tests Pharmacotherapy Selection System that Aims to Improve the Impact of Diabetes Treatment"
bit.ly/3wJ1Ax4

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company's consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.

About University of Utah Health

University of Utah Health provides leading-edge and compassionate medicine for a referral area that encompasses 10% of the U.S., including Idaho, Wyoming, Montana and much of Nevada. A hub for health sciences research and education in the region, U of U Health has a
$428 million research enterprise and trains the majority of Utah's physicians, including more than 1,250 health care providers each year at its Schools of Medicine and Dentistry and Colleges of Nursing, Pharmacy and Health. With more than 20,000 employees, the system includes 12 community clinics and four hospitals. For ten straight years, U of U Health has ranked among the top 10 U.S. academic medical centers in the Vizient Quality and Accountability Study.

About Regenstrief Institute

Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national, and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute's research mission.

Business Contacts:

Research & Development Group, Hitachi, Ltd.
bit.ly/3qw4CRy

The University of Utah Health 30N 1900E
Salt Lake City, UT 84132 Julie Kiefer
(801) 587-1293
Julie.kiefer@hsc.utah.edu

Regenstrief Institute 1101 West Tenth Street Indianapolis, IN 46202 John Erickson
(317) 643-2313
joerick@regenstrief.org


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment.
Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Tokyo and Salt Lake City, Indianapolis, Mar 25, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of vision and kidney disease.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Image of the AI grouping patients and analyzing the treatment patterns & efficacy

For this smaller group of patients, physicians may have limited clinical decision-making experience or evidence-based guidance for choosing drug combinations. The solution is to expand the number of patients to support development of general principles to guide decision- making. Combining patient data from multiple healthcare institutions, however, requires deep expertise in artificial intelligence (AI) and wide-ranging experience in developing machine learning models using sensitive and complex healthcare data.

Hitachi, U of U Health, and Regenstrief researchers partnered to develop and test a new AI method that analyzed electronic health record data across Utah and Indiana and learned generalizable treatment patterns of type 2 diabetes patients with similar characteristics. Those patterns can now be used to help determine an optimal drug regimen for a specific patient.

Some of the results of this study are published in the peer-reviewed medical journal, Journal of Biomedical Informatics, in the article, "Predicting pharmacotherapeutic outcomes for type 2 diabetes: An evaluation of three approaches to leveraging electronic health record data from multiple sources". (bit.ly/3NvD7BE)

Hitachi had been working with U of U Health for several years on development of a pharmacotherapy selection system for diabetes treatment(1) . However, the system was not always able to accurately predict more complex and less prevalent treatment patterns because it did not have enough data. In addition, it was not easy to use data from multiple facilities, as it was necessary to account for differences in patient disease states and therapeutic drugs prescribed among facilities and regions. To address these challenges, the project partnered with Regenstrief to enrich the data it was working with.

The new AI method initially groups patients with similar disease states and then analyzes their treatment patterns and clinical outcomes. It then matches the patient of interest to the disease state groups and predicts the range of potential outcomes for the patient depending on various treatment options. The researchers evaluated how well the method worked in predicting successful outcomes given drug regimens administered to patients with diabetes in Utah and Indiana. The algorithm was able to support medication selection for more than 83 percent of patients, even when two or more medications were used together.

In the future, the research team expects to help patients with diabetes who require complex treatment in checking the efficacy of various drug combinations and then, with their doctors, deciding on a treatment plan that is right for them. This will lead not only to better management of diabetes but increased patient engagement, compliance, and quality of life.

The three parties will continue to evaluate and improve the effectiveness of the new AI method and contribute to future patient care through further research in healthcare informatics.

Hitachi will accelerate efforts, including the practical application of this technology through collaboration between its healthcare and IT business divisions and R&D group. GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, is promoting healthcare- related projects in the U.S., will also deepen the collaboration in this field. Through these efforts, the entire Hitachi group will contribute to the health and safety of people.

(1) Hitachi, Ltd. news release, March 12, 2018 "Pharmacotherapy Selection System Supports Shared Clinician- patient Decision-Making in Diabetes Treatment"
bit.ly/3Ld97Z7
Hitachi, Ltd. news release, February 27, 2019 "New Clinical Study Tests Pharmacotherapy Selection System that Aims to Improve the Impact of Diabetes Treatment"
bit.ly/3wJ1Ax4

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company's consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.

About University of Utah Health

University of Utah Health provides leading-edge and compassionate medicine for a referral area that encompasses 10% of the U.S., including Idaho, Wyoming, Montana and much of Nevada. A hub for health sciences research and education in the region, U of U Health has a
$428 million research enterprise and trains the majority of Utah's physicians, including more than 1,250 health care providers each year at its Schools of Medicine and Dentistry and Colleges of Nursing, Pharmacy and Health. With more than 20,000 employees, the system includes 12 community clinics and four hospitals. For ten straight years, U of U Health has ranked among the top 10 U.S. academic medical centers in the Vizient Quality and Accountability Study.

About Regenstrief Institute

Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national, and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute's research mission.

Business Contacts:

Research & Development Group, Hitachi, Ltd.
bit.ly/3qw4CRy

The University of Utah Health 30N 1900E
Salt Lake City, UT 84132 Julie Kiefer
(801) 587-1293
Julie.kiefer@hsc.utah.edu

Regenstrief Institute 1101 West Tenth Street Indianapolis, IN 46202 John Erickson
(317) 643-2313
joerick@regenstrief.org


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment.

Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Tokyo and Salt Lake City, Indianapolis, Mar 25, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of vision and kidney disease.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Image of the AI grouping patients and analyzing the treatment patterns & efficacy

For this smaller group of patients, physicians may have limited clinical decision-making experience or evidence-based guidance for choosing drug combinations. The solution is to expand the number of patients to support development of general principles to guide decision- making. Combining patient data from multiple healthcare institutions, however, requires deep expertise in artificial intelligence (AI) and wide-ranging experience in developing machine learning models using sensitive and complex healthcare data.

Hitachi, U of U Health, and Regenstrief researchers partnered to develop and test a new AI method that analyzed electronic health record data across Utah and Indiana and learned generalizable treatment patterns of type 2 diabetes patients with similar characteristics. Those patterns can now be used to help determine an optimal drug regimen for a specific patient.

Some of the results of this study are published in the peer-reviewed medical journal, Journal of Biomedical Informatics, in the article, "Predicting pharmacotherapeutic outcomes for type 2 diabetes: An evaluation of three approaches to leveraging electronic health record data from multiple sources". (bit.ly/3NvD7BE)

Hitachi had been working with U of U Health for several years on development of a pharmacotherapy selection system for diabetes treatment(1) . However, the system was not always able to accurately predict more complex and less prevalent treatment patterns because it did not have enough data. In addition, it was not easy to use data from multiple facilities, as it was necessary to account for differences in patient disease states and therapeutic drugs prescribed among facilities and regions. To address these challenges, the project partnered with Regenstrief to enrich the data it was working with.

The new AI method initially groups patients with similar disease states and then analyzes their treatment patterns and clinical outcomes. It then matches the patient of interest to the disease state groups and predicts the range of potential outcomes for the patient depending on various treatment options. The researchers evaluated how well the method worked in predicting successful outcomes given drug regimens administered to patients with diabetes in Utah and Indiana. The algorithm was able to support medication selection for more than 83 percent of patients, even when two or more medications were used together.

In the future, the research team expects to help patients with diabetes who require complex treatment in checking the efficacy of various drug combinations and then, with their doctors, deciding on a treatment plan that is right for them. This will lead not only to better management of diabetes but increased patient engagement, compliance, and quality of life.

The three parties will continue to evaluate and improve the effectiveness of the new AI method and contribute to future patient care through further research in healthcare informatics.

Hitachi will accelerate efforts, including the practical application of this technology through collaboration between its healthcare and IT business divisions and R&D group. GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, is promoting healthcare- related projects in the U.S., will also deepen the collaboration in this field. Through these efforts, the entire Hitachi group will contribute to the health and safety of people.

(1) Hitachi, Ltd. news release, March 12, 2018 "Pharmacotherapy Selection System Supports Shared Clinician- patient Decision-Making in Diabetes Treatment"
bit.ly/3Ld97Z7
Hitachi, Ltd. news release, February 27, 2019 "New Clinical Study Tests Pharmacotherapy Selection System that Aims to Improve the Impact of Diabetes Treatment"
bit.ly/3wJ1Ax4

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company's consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.

About University of Utah Health

University of Utah Health provides leading-edge and compassionate medicine for a referral area that encompasses 10% of the U.S., including Idaho, Wyoming, Montana and much of Nevada. A hub for health sciences research and education in the region, U of U Health has a
$428 million research enterprise and trains the majority of Utah's physicians, including more than 1,250 health care providers each year at its Schools of Medicine and Dentistry and Colleges of Nursing, Pharmacy and Health. With more than 20,000 employees, the system includes 12 community clinics and four hospitals. For ten straight years, U of U Health has ranked among the top 10 U.S. academic medical centers in the Vizient Quality and Accountability Study.

About Regenstrief Institute

Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national, and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute's research mission.

Business Contacts:

Research & Development Group, Hitachi, Ltd.
bit.ly/3qw4CRy

The University of Utah Health 30N 1900E
Salt Lake City, UT 84132 Julie Kiefer
(801) 587-1293
Julie.kiefer@hsc.utah.edu

Regenstrief Institute 1101 West Tenth Street Indianapolis, IN 46202 John Erickson
(317) 643-2313
joerick@regenstrief.org


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment.

Bored Ape Yacht Club Guide: BAYC, ApeCoin, and the Apeverse

The Bored Ape Yacht Club (BAYC) is an exclusive membership project open to any and all owners of the Bored Ape Yacht Club NFT, underpinned by the ApeCoin (APE) token.…

The post Bored Ape Yacht Club Guide: BAYC, ApeCoin, and the Apeverse appeared first on CoinCentral.

Into the metaverse: Alfa Romeo F1 Team ORLEN joins Everdome

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Dubai, United Arab Emirates, 24th March, 2022, Chainwire Alfa Romeo F1 Team ORLEN will make a huge step towards its

The post has appeared first on thenewscrypto.com

SEC Proposes Sweeping Greenhouse Gas Reporting Rules Which Would Affect Crypto Mining

The U.S. Securities and Exchange Commission (SEC) has proposed new rule changes that would require registrants to provide climate-related disclosures to the SEC. It would also require companies to disclose climate-related risks which would be “reasonably likely” to have a material impact on their business, result of operations, or financial condition. “I am pleased to […]

The post SEC Proposes Sweeping Greenhouse Gas Reporting Rules Which Would Affect Crypto Mining appeared first on Coin Bureau.

Value Research Center (VRC) develops Value Model integrating ESG and Sustainability Measures

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

KYOTO, Japan, Mar 24, 2022 - (JCN Newswire) - The Value Research Center (VRC) has launched an integrated Value Model with ESG and Sustainability measures in a new white paper issued today. With the shift from short term, profit-focused thinking towards long-term, sustainable, value-focused thinking, businesses globally need to answer a fundamental question: "What value are you providing our collective future?"

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
A Value Model for Responsible Business: The new Value Research Center (VRC) white paper was officially released today. The VRC initiative is aimed at improving company performance and social impact.

The VRC at Doshisha University was established in November 2021 to create a Value Model that could guide any company to answer this question, so ensuring a more sustainable future. The VRC published its initial white paper, "Valuing Value", in June 2021, integrating 357 impact measurements from 15 of the world's top ESG and sustainability frameworks and developing a 7-stakeholder, 27-theme, 80-goal model to help businesses objectively and transparently measure and manage the value impacts that they have on their key stakeholders.

The VRC's new white paper entitled "A Value Model for Responsible Business", integrates an additional 346 impact measurements from 6 new frameworks into the initial model. These 6 frameworks include the International Sustainability Standards Board (ISSB) Prototype Climate-related disclosures; Task Force on Climate-related Financial Disclosure (TCFD) guidance on metrics, targets and transition plans; Stockholm Resilience Center's Planetary Boundaries; United Nations Development Program (UNDP) SDG Impact Standards for Enterprises; International Finance Corporation (IFC) Performance Standards; and Science Based Targets initiative (SBTi) climate disclosures.

The white paper is available for download: https://www.valueresearchcenter.com/2022whitepaper

Professor Philip Sugai, Director of the VRC, says "Our team analyzed hundreds of existing impact measurements and organized these into 27 common themes with 81 goals that any company, regardless of size, industry or location can use to measure, manage and use to consistently increase the value they create for stakeholders. Unlike existing ESG or sustainability reporting models, the VRC Value Model offers companies the ability to track their actual stakeholder impacts, using this data to create forward-looking strategies aimed at further increasing the value they create for and with these stakeholders."

Masato Yamazaki, Professor Emeritus of Economics at Aquinas College, Grand Rapids, Michigan, and VRC operating council member, said "The Value Model that our VRC research team offers is a more advanced approach than any other sustainability model or approach in existence today, since it can automatically help identify the root causes of the problems companies face via well-developed assessment tools."

"What is needed in sustainability efforts today goes beyond simple reporting," says Dr. Kumar Iyer, Mentor for Value Creation and VRC operating council member. "The VRC Value Model is based on objective metrics and quantifiable indicators which can be independently verified. This is uniquely different from any other sustainability reporting approach as it is directly linked to creating social impact.

About the Value Research Center (VRC)

The Value Research Center (VRC) was officially established at Doshisha University in Kyoto, Japan in 2021. The VRC is mandated to research and develop an open, accessible and transparent system for assessing and reporting on value creation (destruction) impacts that organizations of every size have over seven stakeholder groups: (1) the organization itself, (2) shareholders or owners, (3) customers, (4) employees, (5) partners, (6) the society within which it operates, and (7) the planet.

The VRC ensures that all relevant stakeholders which businesses impact are covered by assessment, and regularly updated based on scientific data. As part of the Doshisha University network, we bear the reputation of our parent and its stature as a global organization affiliated with world leading Universities that we call partners. Learn about VRC and its research at https://www.valueresearchcenter.com, or email Prof Philip Sugai at info@valueresearchcenter.com.

* Webinar, March 25 - IAFOR in discussion with VRC Director Philip Sugai
Dr. Joseph Haldane, Chairman & CEO of the International Academic Forum (IAFOR) will discuss the contents of this new white paper with VRC Director Prof. Philip Sugai in a Webinar on Friday, March 25, 5:00 - 6:00 pm JST, in collaboration with the new ESG-IREC Research Center at Osaka University. This webinar will be free to attend, and reservations can be made at: https://tinyurl.com/IRC-VRC-20220325

About the IAFOR Research Center (IRC)
The IRC aims to provide a research centre to nurture various international and interdisciplinary research policies that use the extensive networks of both Osaka University and IAFOR. https://iafor.org/.

About the ESG-IREC Research Center
The Osaka University Graduate School of International Public Policy - ESG Integration Research and Education Center (ESG-IREC) conducts research on practical implementable "ESG integration" models in corporate and business activities for the creation of a more sustainable future. https://www.osipp.osaka-u.ac.jp/en/.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comThe Value Research Center (VRC) launched an integrated Value Model with ESG and Sustainability measures in a new white paper issued today. With the shift from short term, profit-focused thinking towards long-term, sustainable, value-focused thinking, businesses globally need to answer a fundamental question: "What value are you providing our collective future?"
Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Recent articles

spot_img